Donanemab, Eli Lilly’s Early Alzheimer’s Disease Treatment Approved By FDA

Donanemab is a monoclonal antibody that the U.S. Food and Drug Administration (FDA) approved on Tuesday with the goal of slowing the progression of early-stage symptomatic Alzheimer's disease.